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forRecent clinical trials in patients with heart failure with preserved ejection fraction (HFpEF) have provided important
insights into participant selection strategies. Historically, HFpEF trials have included patients with relatively preserved
left ventricular ejection fraction ranging from 40% to 55% and a clinical history of heart failure. Contemporary HFpEF
trials have also incorporated inclusion criteria such as hospitalization for HFpEF, altered functional capacity, cardiac
structural and functional abnormalities, and abnormalities in neurohormonal status (e.g., elevated natriuretic peptide
levels). Careful analyses of the effect of these patient selection criteria on outcomes in prior trials provide valuable
lessons for future trial design. We review recent and ongoing HFpEF clinical trials from a patient selection perspective
and appraise trial patient selection methodologies in relation to outcomes. This review reﬂects discussions between
clinicians, scientists, trialists, regulators, and regulatory representatives at the 10th Global CardioVascular Clinical Tria-
lists Forum in Paris, France, on December 6, 2013. (J Am Coll Cardiol 2015;65:1668–82) © 2015 by the American College
of Cardiology Foundation.H eart failure with preserved ejection fraction(HFpEF) currently represents almost one-half of all heart failure (HF) patients and,
with the growing elderly population, is projected to
become the predominant form of HF in the future
(1,2). HFpEF represents a large unmet need in cardio-
vascular medicine. Over 5 million Americans and
23 million people worldwide have HF, of which pa-
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AB BR E V I A T I O N S
AND ACRONYM S
EF = ejection fraction
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
NP = natriuretic peptide
PASP = pulmonary artery
systolic pressure
PCWP = pulmonary capillary
wedge pressure
VAS-AUC = visual analog scale
under the curve
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1669have been neutral. Important lessons can be learned
from these prior trials. In this paper, we summarize
recent and ongoing HFpEF clinical trials and appraise
trial methodologies from the perspective of patient
selection to critically inform the design of future ran-
domized clinical trials for clinicians, researchers, and
patients.
GUIDELINE DEFINITIONS FOR HFpEF
Recommendations for the diagnosis of patients
with HFpEF are similar in scope and depth across
the most recent U.S. and European guidelines (6–9).
The most recent American College of Cardiology/
American Heart Association guidelines deﬁned
HFpEF as patients with ejection fraction (EF) $50%
with symptoms suggestive of HF and exclusion of
other potential noncardiac etiologies of HF. The
guidelines also include subpopulations of borderline
HFpEF with EF 41% to 49% and HFpEF with improved
EF >40% for patients who previously had reduced EF
(6). The 2012 European Society of Cardiology guide-
lines deﬁned 4 requirements to diagnose HFpEF,
including: 1) symptoms typical of HF; 2) signs typical
of HF; 3) normal or only mildly reduced left ventric-
ular EF without left ventricular dilation; and 4) rele-
vant structural heart disease (left ventricular
hypertrophy/left atrial enlargement) and/or diastolic
dysfunction (Table 1) (8,9). The underlying patho-
physiologic mechanisms behind HFpEF involve, in
part, a diffuse inﬂammatory state that develops from
the constellation of such frequently coexisting
comorbidities as chronic obstructive lung disease,
anemia, diabetes mellitus, renal dysfunction, and
obesity in patients with HFpEF (10,11). The proin-
ﬂammatory state limits the available nitric oxide in
the coronary microvasculature and shifts cardiac
remodeling toward hypertrophy and interstitial
ﬁbrosis, which increases left ventricular diastolic
stiffness and the conditions for HFpEF (12).
DEFINITIONS IN CLINICAL TRIALS
The ﬁrst large clinical trial that focused on patients
with HFpEF, the CHARM (Candesartan in HeartServier, Boston Scientiﬁc, Bayer, Johnson & Johnson, and ResMed. Dr. Pitt
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and Morbidity) Preserved trial, required an
EF >40%, New York Heart Association
(NYHA) functional class II to IV symptoms for
>4 weeks, and any prior hospital admission
for a cardiac reason (13). This deﬁnition was
analogous to HFrEF trials at the time, where
EF cutpoints <35% and <45% were used in
addition to HF symptoms or known history
of HF (14,15). As the results from clinical
trials and secondary analyses in these HFpEF
populations without use of guideline criteria
revealed low event rates and limited beneﬁts
from traditional HF therapies, clinical tria-
lists subsequently adjusted entry criteria
(16). The EF criterion was increased, echocardio-
graphic parameters were incorporated, and eventu-
ally, natriuretic peptide (NP) levels were included in
a combined deﬁnition that also required HF symp-
toms (Table 2). Preserved EF $50%, symptoms and/
or hospitalization for HF, echocardiographic ﬁndings,
and elevated NP levels exempliﬁed the prevailing
thought that HFpEF was primarily a disease of
elderly women with stiff left ventricles from long-
standing hypertension and concomitant diabetes
mellitus. However, clinical trials, cohort studies, and
registry analyses have demonstrated that the HFpEF
population is heterogeneous, particularly with re-
spect to comorbidities (11). Future clinical trials in
HFpEF may beneﬁt from further reﬁnement of these
key patient selection criteria to optimize the poten-
tial for success.
EJECTION FRACTION
EF was the ﬁrst inclusion criterion used to differ-
entiate patients with HFrEF from HFpEF. The ﬁrst 3
large HFpEF trials studied renin-angiotensin aldo-
sterone system inhibition with EF cutoffs of 40% to
45% (13,17,18). More recent trials have split between
using an EF cutoff $45% and $50%. The PARA-
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on Management Of heart failUre with preserved
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TABLE 1 Summary of HFpEF Diagnosis Guidelines
Guidelines Diagnosis
ESC (9) The following 4 criteria are required: 1) symptoms
typical of HF; 2) signs typical of HF; 3) normal or
only mildly reduced LVEF and LV not dilated;
and 4) relevant structural heart disease (LV
hypertrophy/LA enlargement) and/or diastolic
dysfunction.
ACC/AHA:
HFpEF (6)
Diastolic HF. Multiple criteria have been used;
exclude other potential noncardiac causes of
symptoms suggestive of HF.
ACC/AHA: EF
41%–49%
Borderline or intermediate EF; these patients have
similar characteristics, treatment patterns, and
outcomes to those with HFpEF
ACC/AHA:
improved EF
Patients previously with HFrEF; improved or
recovered EF clinically distinct from patients
with preserved or reduced EF.
HFSA (7) Patients with EF $50% with symptoms suggestive
of HF. Use echocardiography, ECG, stress
imaging, or cardiac catheterization to distinguish
HF with preserved LVEF and other cardiac
disorders.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; ECG ¼
electrocardiogram; ESC ¼ European Society of Cardiology; HF ¼ heart failure;
HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with
reduced ejection fraction; HFSA ¼ Heart Failure Society of America; LA ¼ left
atrial; LV ¼ left ventricle; LVEF ¼ left ventricular ejection fraction.
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onist trial) trials used an EF cutoff for participant
inclusion of $45% (19,20). This cutoff choice be-
tween trials in HFrEF and HFpEF has left a largely
unstudied intermediate EF group including 10% to
15% (5,21) of the overall HF population with an EF
between 40% and 50%. The CHARM pooled analyses
and the American Heart Association’s GWTG-HF
(Get With the Guidelines–Heart Failure) initiative
have a bell-shaped EF distribution with 17% (n ¼
1,295) and 14% (n ¼ 15,184) of patients with an EF
of 40% to 50%, respectively (5). However, the
OPTIMIZE-HF (Organized Program to Initiate Life-
saving Treatment in Hospitalized Patients with
Heart Failure) Registry and Olmstead County study
have bimodal EF distributions, with relatively few
patients with an EF of 40% to 50%, suggesting that
real-world populations may have fewer patients in
this intermediate range than clinical trials (4,21,22).
The clinical characteristics and clinical outcomes of
patients with an EF between 40% and 50% appear
to be intermediate compared with patients with
HFrEF and HFpEF, and the etiology of the mild
reduction in EF varies (partial EF recovery or
primary HFpEF) (21–23).
It is unknown which EF cutoff provides the most
reliable discriminator to enhance enrollment of the
HFpEF phenotype and associated event rates. The
MAGGIC (Meta-analysis Global Group in Chronic
Heart Failure) meta-analysis demonstrated a clear
increase in event rates when EF <40% was compared
with >40% (24). The utility of this EF cutpoint was
also demonstrated in the OPTIMIZE-HF registry,
where multivariable analyses revealed that in-
hospital mortality risk for patients with EF between
40% and 50% was similar to those with EF >50%.
Speciﬁcally, in-hospital mortality decreased by 17%
for every 10% increase in EF up to 38%, with no
further association with increased mortality above
an EF of 38% (22). The CHARM pooled analyses
demonstrated an increased risk for all-cause mortal-
ity and cardiovascular death with EF <45% (25).
When event rates in the CHARM pooled analyses were
evaluated for patients with HFpEF using an EF $40%
and repeating the same analysis with an EF $50%, the
event rates were unchanged (26). A secondary anal-
ysis from SENIORS (Study of the Effects of Nebivolol
Intervention on Outcomes and Rehospitalisation in
Seniors with Heart Failure) revealed similar primary
event rates for patients with HFpEF deﬁned on the
basis of an EF >35% or $40% (27). The placebo arms
of HF clinical trials using lower EF cutoffs, such as EF
>40%, reveal similar event rates to clinical trials with
EF cutoffs $45% or $50% (Table 2). Although theevent rates from the placebo arms across EF cutoffs
from 40% to 50% are similar, using an EF cutoff
of $40% or $45% risks including patients with an
intermediate EF who may have different character-
istics, such as more ischemic heart disease.
The historical precedence for using EF cutoffs for
HFrEF <40% or #35% versus $40%, 45%, or 50%
for HFpEF, combined with equal event rates across
a range of EFs $40% to 50%, leaves us with 3 fu-
ture clinical design options, including: 1) using an
EF $40% to prevent an intermediate EF gap; 2) us-
ing a higher EF of $45% or $50% and deﬁning
the created intermediate EF group; or 3) lessening
the effect of EF as an inclusion criterion. There is
no clear absolute EF inclusion criterion; however,
insightful use of EF as an inclusion criterion with
an eye toward the preferred HFpEF phenotype will
lead to successful trials. For example, if a clinical
trial is studying a pharmaceutical therapy aimed
at HFpEF patients with hypertension and associated
structural remodeling, then use of a higher EF (e.g.,
50%) inclusion criterion will enrich the trial with
the preferred phenotype. However, if a promising
new therapy appears to work across a more hetero-
geneous HFpEF population, then use of a lower
EF (e.g., 40%) inclusion criterion will potentially
make the results of the trial generalizable. Ulti-
mately, the use of EF as an inclusion criterion
requires appropriate insight into the HFpEF pheno-
type that will beneﬁt most from the therapy under
investigation.
TABLE 2 Inclusion Criteria in Selected Previous and Ongoing Clinical Trials and Registries of Patients With HFpEF
Trial (Ref. #) Clinical Dx HF
Prior HF
Admission, % EF, %
Atrial Fibrillation/
Atrial Flutter, % BNP,* pg/ml
NT-proBNP,*
pg/ml
Event Rate†
(1 yr) Primary Endpoint Clinical Findings
CHARM-PRESERVED (13) NYHA II to IV >4 weeks,
hospitalized for cardiac
reason, history of hospital
admission for cardiac reason
68.8 >40 29.3 — — 9.1% CV death or HF
hospitalization
No reduction in CV death;
fewer patients in
treatment group had
HF hospitalization
PEP-CHF (17) Age $70 yrs, on diuretics, echo
with DD, 3 of 9 clinical,
2 of 4 echo criteria, CV
hospitalization within
6 months
100 >40 22 — 453 13.2% Composite of all-cause
mortality and
unplanned HF
hospitalization
No reduction in all-cause
mortality or HF
hospitalization
DIG-PEF (87) NSR, HF symptoms — >45 0 — — 7.8 per 100
patient-yrs
Combined HF
hospitalization or
HF mortality
Digoxin had no effect on
mortality or all-cause
CV hospitalization
SENIORS (27) Age $70 yrs, HF history þ $1
HF hospitalization, or
EF #35% within past
6 months
— >35 37.1 — — 19.2 per 100
patient-yrs
All-cause mortality or
CV hospitalizations
No difference in effect of
nebivolol on elderly
patients with HFpEF
vs. HFrEF
I-PRESERVE (18) NYHA functional class II–IV 44 $45 17 — 320 10.5 per 100
patient-yrs
All-cause mortality or
CV hospitalization
No improvement from
irbesartan in primary
endpoints
ELANDD (88) NYHA functional class II–III, echo
DD
— >45 — — 126 — Change in 6MWD after
6 months
No change in 6MWD or
peak VO2
J-DHF (89) Modiﬁed Framingham criteria
for HF within 12 months
60 >40 45.6 235
(mean)
— 8.5 per 100
patient-yrs
Composite of CV death
and unplanned HF
hospitalization
No improvement from
carvedilol
ALDO-DHF (51) Ambulatory NYHA functional
class II–III HF, echo DD
36 $50 4 — 148 — Coprimary: change in
diastolic function
(E/e0) and peak VO2
at 12 months
Improved DD but no change
in peak VO2
Ex-DHF (90) Symptomatic NYHA functional
class II–III outpatients,
age $45 yrs, DD grade $1,
NSR, 1 CV risk factor
— $50 — — — — Change in peak VO2 after
3 months
Peak VO2 increased
3.3 ml/min/kg, E/e0
and LAVI decreased
PARAMOUNT (20) NYHA functional class II–IV 45 $45 43 — >400 — Change in NT-proBNP
from BL to 12 weeks
LCZ696 reduced NT-
proBNP more than
valsartan at
12 weeks
RELAX (50) Stable outpatients with HF,
elevated NT-proBNP, or
elevated ﬁlling pressures,
reduced exercise capacity
39 $50 50 — 648 — Change in peak VO2 after
24 weeks of therapy
No improvement in peak
VO2
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TABLE 2 Continued
Trial (Ref. #) Clinical Dx HF
Prior HF
Admission, % EF, %
Atrial Fibrillation/
Atrial Flutter, % BNP,* pg/ml
NT-proBNP,*
pg/ml
Event Rate†
(1 yr) Primary Endpoint Clinical Findings
RELAX-AHF (91) Admitted for AHF (dyspnea at
rest or minimum exertion,
pulmonary congestion on
chest radiograph, and
BNP $350 pg/ml or NT-
proBNP $1,400 pg/ml and
eGFR 30–75 ml/min/1.73 m2
29.5 $50 61.2 — 3,992 12.8%‡ Change from BL in VAS-
AUC to day 5 and
proportion of patients
with improved
dyspnea by Likert
scale during ﬁrst 24 h
Improved dyspnea relief by
the VAS-AUC and Likert
scale
RAAM-PEF (92) NYHA functional class II–III,
clinical HF, and BNP $100
pg/ml within 2 months
60.9 $50 13 284 — — Change in 6MWD No change in 6MWD
SHIFT-PRESERVED (68) Signs or symptoms of HF,
echo with DD, exercise
capacity <80% age/sex
predicted, E/e0 >13 after
exercise
— $50 — 62 — — Exercise capacity, E/e0 Improved peak VO2 and
improved E/e0 after
exercise
TOPCAT (19) History of hospitalization within
the previous 12 months, with
management of HF a major
component of the care
provided or an elevated NP
level within 60s days before
randomization
71.5 $45 >100
235
>360
1,017
6.6 per 100
patient-yrs
Composite of CV
mortality, aborted
cardiac arrest, or
hospitalization for HF
No improvement in
composite endpoint
Enrollment on the basis of HF
hospitalization as a major
component in the past 1 yr
— — — — — 6.0 per 100
patient-yrs
— —
Enrollment on the basis of BNP/
NT-proBNP criteria
— — — — — 8.5 per 100
patient-yrs
— —
Enrollment in the Americas — — — — — 12.6 per 100
patient-yrs
— —
Enrollment in Eastern Europe — — — — — 2.3 per 100
patient-yrs
— —
PARAGON-HF (93) NYHA functional class II–IV
requiring treatment with
diuretic agents for $30 days,
LAE or LVH by echo, and HF
hospitalization within 9
months or elevated
NT-proBNP
— $45 — — Elevated — Composite endpoint of
CV death and total HF
hospitalizations (ﬁrst
and recurrent)
—
SOCRATES-PRESERVED (94) Worsening HF requiring
hospitalization or IV diuretic
agent as outpatient
— $45 — — — — NT-proBNP from BL to
12 weeks, change of
LAVI, safety
—
EDIFY (95) Stable symptomatic NYHA
functional class II-III $3
months, HR in sinus rhythm
>70, E/e0 >13 or e0 lateral <10
cm/s and e0 septal <8 cm/s, or
LAVI >34 ml/m2
— $45 — $80 $220 — Diastolic function (E/e0),
NT-proBNP, and
6MWD
—
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TABLE 2 Continued
Trial (Ref. #) Clinical Dx HF
Prior HF
Admission, % EF, %
Atrial Fibrillation/
Atrial Flutter, % BNP,* pg/ml
NT-proBNP,*
pg/ml
Event Rate†
(1 yr) Primary Endpoint Clinical Findings
Ontario, Canada (29) 1st time admission for HF (only) on
the basis of Framingham HF
criteria
— >50 31.8 — — 22.2% Death from any cause
after the index
hospitalization for HF
31.1% composite 1-yr
mortality or readmission
for HF, 22.2% 1-yr
mortality, 13.5% 1-yr
readmission for HF,
9.4% 30-day mortality
or readmission for HF
Olmsted County (4) All consecutive patients
hospitalized at Mayo Clinic
hospitals from 1987–2001 (ICD
code 428 and DRG code 127)
— $50 41.3 — — 29% Mortality rate at 1 yr Increased prevalence of
HFpEF with similar rate
of death over a 15-yr
period
ADHERE (96) AHF as new-onset HF or
decompensated chronic HF
with symptoms requiring
hospitalization; ICD-9
discharge diagnosis of HF
63 $40 21
(1st ECG)
— — 2.8% In-hospital mortality In-hospital mortality was
lower in patients with
HFpEF vs. HFrEF
OPTIMIZE-HF (22) Hospitalized new-onset or
worsening HF as primary cause
of admission or signiﬁcant HF
symptoms that developed
during hospitalization with HF
as primary discharge diagnosis
—
—
$40
>50
33
32
602
537
—
—
35.3%
36.8%
Post-discharge mortality/
rehospitalization at
60-90 days
HFpEF and HFrEF had
similar lengths of
hospital stay, in-
hospital mortality was
lower in HFpEF
MAGGIC (24) Meta-analysis of observational
studies and RCTs through
2006, with eligible studies
including patients with HF and
death from any cause where
EF criterion was not used for
study entry
— $50 27 — — 12.1 per 100
patient-yrs
Death from any cause HFpEF patients have a
lower risk of death than
patients with HFrEF but
absolute mortality in
HFpEF is still high
GWTG-HF (5) Hospitalization for acute,
decompensated HF on the
basis of clinical diagnosis
54
56
$50
40–49
34
34
551
761
3,401
5,495
2.5%
2.3%
In-hospital mortality Hospitalization for HFpEF is
increasing relative to
HFrEF, with in-hospital
mortality for HFpEF
declining over study
period
*NP levels are median levels unless otherwise speciﬁed, and if used as inclusion criteria they are listed with > or < symbols. †Data are in percentages or 100 patient-years and from placebo groups in clinical trials unless otherwise noted. ‡RELAX-AHF event rate is
cardiovascular death or HF/renal failure hospitalization through day 60.
ADHERE ¼ Acute Decompensated Heart Failure Registry; AHF ¼ acute heart failure; ALDO-DHF ¼ Aldosterone receptor blockade in Diastolic Heart Failure; BL ¼ baseline; BNP ¼ B-type natriuretic peptide; CHARM-PRESERVED ¼ Candesartan in Patients With Heart
Failure and Preserved Left Ventricular Systolic Function; CV ¼ cardiovascular; DD ¼ diastolic dysfunction; DIG-PEF ¼ Digitalis Intervention Group-Preserved Ejection Fraction; DRG ¼ diagnosis-related group; Dx ¼ diagnosis; EDIFY ¼ Effect of ivabradine versus placebo
on cardiac function and on capacity to perform exercise in patients suffering from diastolic heart failure; E/e0 ¼ peak early transmitral ventricular ﬁlling velocity/early diastolic tissue Doppler velocity; echo ¼ echocardiography; EF ¼ ejection fraction; eGFR ¼ estimated
glomerular ﬁltration rate; ELANDD ¼ Effects of Long-term Administration of Nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with Diastolic Dysfunction; Ex-DHF ¼ Exercise Training in Diastolic Heart Failure; GWTG-HF ¼
Get With the Guidelines Heart Failure; ICD ¼ International Classiﬁcation of Diseases; I-PRESERVE ¼ Irbesartan in patients with heart failure and preserved ejection fraction; IV ¼ intravenous; J-DHF ¼ Japanese Diastolic Heart Failure; LAE ¼ left atrial enlargement;
LAVI ¼ left atrial volume index; LVH ¼ left ventricular hypertrophy; MAGGIC ¼Meta-analysis Global Group in Chronic Heart Failure; NSR ¼ normal sinus rhythm; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; OPTIMIZE-
HF ¼ Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure; PARAGON-HF ¼ Efﬁcacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction;
PARAMOUNT ¼ Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fraction; PEP-CHF ¼ Perindopril in elderly people with chronic heart failure; RAAM-PEF ¼ Randomized Aldosterone Antagonism in Heart Failure With
Preserved Ejection Fraction; RCT ¼ randomized controlled trial; RELAX ¼ The Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction; RELAX-AHF ¼ RELAXin in Acute Heart Failure; SENIORS ¼
Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure; SHIFT-PRESERVED ¼ Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Preserved; SOCRATES-PRESERVED ¼ Phase IIb Safety and Efﬁcacy
Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure; TOPCAT ¼ Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist; VAS-AUC ¼
visual analog scale-area under curve; VO2 ¼ peak oxygen consumption; 6MWD ¼ 6 min walk distance; other abbreviations as in Table 1.
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Prior hospitalization for HF is a powerful predictor of
future outcomes. Investigators pooled the CHARM
clinical trials and used a time-updated Cox propor-
tional hazards model to show that the mortality rate
increased after HF hospitalization for upwards of 6
months from time of discharge to randomization (26).
This observation was also independent of EF. Longer
hospitalization and repeat hospitalization also in-
creased the risk of mortality. The time period early
after discharge from hospitalization for HF represents
a particularly high-risk window for mortality. This
high-risk period may also represent an opportunity to
enrich event rates in clinical trials (28). A large pop-
ulation study in Ontario, Canada, reported 1-year HF
readmission rates of 16.1% and 13.5% (p ¼ 0.09) for
HFrEF and HFpEF, respectively, whereas the unad-
justed combined 1-year endpoint of death and HF
readmission was 36.1% and 31.1% for HFrEF and
HFpEF, respectively (p¼0.01) (29). A recent analysis of
the CHARM trials revealed that event rates for mor-
tality and hospitalization were higher in patients
with previous HF hospitalization compared with
those without prior HF hospitalization. Speciﬁcally,
the time interval between prior hospitalization and
randomization was inversely related to the risk for
mortality and hospitalization (i.e., patients more
recently discharged have higher risk of death and re-
admission), and the overall rates between HFrEF and
HFpEF were similar (26). Patients hospitalized for HF
within the previous 6 months in the I-PRESERVE
(Irbesartan in Heart Failure with Preserved Systolic
Function) trial had 10.5 events per 100 patient-years
compared with 4.4 events per 100 patient-years in
those not recently hospitalized for HF (18,30).
Recent HFpEF trials have incorporated the inclu-
sion criterion of prior hospitalization for HF on the
basis of the high risk associated with recent HF hos-
pitalization, as identiﬁed in the CHARM program (26),
but this inclusion criterion has also complicated the
interpretation of trial results. The recent TOPCAT trial
demonstrated that there were regional differences in
how patients entered the trial, speciﬁcally related to
the HF hospitalization criterion. In addition to $1 sign
and symptom of HF, an EF $45%, and controlled
systolic blood pressure, patients were required to
have a history of hospitalization within the previous
12 months, with management of HF a major compo-
nent of the care provided or an elevated NP level
within 60 days before randomization (B-type natri-
uretic peptide [BNP] $100 pg/ml or N-terminal pro-B-
type natriuretic peptide [NT-proBNP] $360 pg/ml). In
the Americas, 39.6% of patients qualiﬁed for the trialon the basis of HF hospitalization within the preced-
ing 12 months compared with 60.4% of patients
from Eastern Europe (19). Unadjusted Cox models by
geographic region and treatment group revealed that
patients enrolled in the Americas control group had
a primary outcome event rate of 31.8%, compared
with 8.4% in patients enrolled in the Eastern Euro-
pean control group. Furthermore, post-hoc analyses
of TOPCAT revealed a 4-fold difference in event rate
in patients enrolled in Russia and Georgia compared
with the Americas, where the primary outcomes
of cardiovascular death and hospitalization were
signiﬁcantly reduced by spironolactone (31). TOPCAT
inclusion criteria required HF to be a major
component of the prior hospitalization, whereas
I-PRESERVE and CHARM required that HF was the
primary cause of hospitalization. This subtle differ-
ence deﬁning previous HF hospitalization inclusion
criteria may have contributed to the low event rates
seen in Russia and Georgia in TOPCAT despite the
high percentage of patients with a history of hospi-
talization (13,18,19). These data support observations
seen in other international clinical trials whereby the
patients enrolled in different regions/countries have
distinct underlying characteristics, treatment pro-
tocols/standards, and event rates (30–34). Hospitali-
zation for HF is an important inclusion criterion
that can drive increased event rates in clinical trials,
but the clinical deﬁnition of HF is subjective, and
nuances pertaining to whether HF is the primary
cause of hospitalization or not are subject to inter-
pretation. Different deﬁnitions, interpretations, and
practice standards may potentially lead to different
event rates.
The use of prior hospitalization as an inclusion
criterion in HFpEF clinical trials can and should be a
powerful driver of event rates. Using hospitalizations
for HF as remote as 12 months has proven successful,
but event rates occur early after discharge; thus,
the use of hospitalizations for HF within 6 months
will increase event rates. Geographical and interna-
tional differences in the deﬁnition and treatment of
patients with HFpEF necessitates further conﬁrma-
tion of clinical HFpEF that can include adjudication
or combining HF hospitalization with a speciﬁc
threshold NP level. Conﬁrming HF hospitalizations or
combining HF hospitalization and NP level entry
criteria will decrease variability in HFpEF patients
and enrich HFpEF event rates.
CLINICAL DIAGNOSIS OF HF
HF is diagnosed on the basis of a clinical assessment
and physical examination, along with supporting data
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1675from the chest radiograph and additional testing.
Despite the added clinical and laboratory informa-
tion, the diagnosis remains largely subjective, with
clinical gestalt on the basis of history, physical
examination, and routinely-obtained laboratory and
hemodynamic measurements. The traditional phys-
ical examination ﬁndings associated with HF, in-
cluding paroxysmal nocturnal dyspnea, jugular
venous distension, and pulmonary rales have sensi-
tivities for left ventricular dysfunction ranging from
17% to 39%, whereas their speciﬁcities range from
77% to 98% (35,36). The NYHA functional class is a
subjective measurement used in HF trials that is
strongly associated with worse outcomes in patients
with HFrEF and HFpEF (37–39). Ultimately, the deci-
sion to hospitalize a patient for HF is determined by
the physician’s interpretation of the patient’s overall
status. Dyspnea severity is the inherent symptom
that inﬂuences decision-making. A recent analysis
revealed that 50% of patients had dyspnea at rest and
that these patients had increased rates of comorbid-
ities, mortality, and HF readmission risk (40).
There are differences in presentations and man-
agement across geographical regions that can chal-
lenge the design and interpretation of clinical trial
results (41). Dyspnea responds quickly to intravenous
diuretic agents, with upwards of three-fourths of pa-
tients responding within 6 h sitting upright versus
47% supine (42). There are multiple dyspnea scales;
those commonly used are the 5- and 7-point Likert
scales and the 10-cm visual analog scale. A post-hoc
analysis of URGENT (Ularitide Global Evaluation in
Acute Decompensated Heart Failure)-Dyspnoea trial
revealed that up to 40% of patients did not have
improved dyspnea in the ﬁrst 6 h; for those who did
improve, patient characteristics differed across all
3 scales, with the c-index ranging from 0.71 to 0.83,
suggesting that improvement in dyspnea may differ
from scale to scale (43). The RELAX-AHF (RELAXin in
Acute Heart Failure) trial evaluating serelaxin used a
visual analog scale area under the curve (VAS-AUC)
endpoint to assess if serelaxin-treated patients would
have improved dyspnea from baseline dyspnea,
congestion on chest radiograph, and elevated NP
levels to day 5 of the VAS-AUC, as well as assessing
the proportion of patients with moderate or marked
dyspnea by the Likert scale during the ﬁrst 24 h (44).
Dyspnea relief, measured by VAS-AUC from baseline
to day 5, was improved in the overall population and
in HFrEF and HFpEF compared with placebo; how-
ever, dyspnea relief at 24 h using the Likert scale was
signiﬁcantly improved in HFpEF patients compared
with placebo, but not in HFrEF with treatment
(interaction p ¼ 0.03). The primary dyspnea endpointof 448 mm improvement using the VAS-AUC score
was signiﬁcant (p ¼ 0.007); however, the coprimary
endpoint using the Likert scale endpoint was not
signiﬁcant through 5 days (p ¼ 0.7). The dyspnea
scoring tools vary from tool to tool and may not al-
ways correspond to hard outcomes. The clinical
diagnosis of HF on the basis of physician assessment,
combined with the use of auxiliary tools, such as
NYHA functional classiﬁcation and dyspnea scores,
will enhance HFpEF clinical trials with patients
experiencing HF symptoms. In patients without clear
HF, adding together dyspnea severity, acute
HF diagnostic prediction models, clinical assessment,
and NP levels has excellent diagnostic accuracy (45).
NP LEVELS
NP levels, such as BNP and its cosecreted biologically-
inactive compound, NT-proBNP, are useful markers
for diagnosing HF and provide prognostic informa-
tion for patients presenting with dyspnea. In more
recent HFpEF trials, NP levels have been used as key
inclusion criteria to: 1) increase the speciﬁcity of the
HFpEF diagnosis; and 2) select patients at higher risk.
Post-hoc analyses from I-PRESERVE reveal that NT-
proBNP is the most powerful independent factor for
the primary outcome of all-cause mortality or car-
diovascular hospitalization in patients with HFpEF
(46,47). The PEP-CHF (Perindopril in Elderly People
with Chronic Heart Failure) trial demonstrated an
increased number of deaths and hospitalization for
HF with higher quartiles of NT-proBNP levels (17). In
the TOPCAT trial, placebo-group patients enrolled on
the basis of NP level had primary outcome event rates
of 23.6% compared with 19.1% in patients enrolled on
the basis of hospitalization in the past year (Table 2)
(19). Using NP-level thresholds for HFpEF clinical trial
entry criteria have driven the HFpEF trials with
higher event rates.
The COACH (Coordinating study evaluating Out-
comes of Advising and Counselling in Heart Failure)
substudy conﬁrmed that NP levels are lower in pa-
tients with HFpEF compared with HFrEF, although
the clinical outcomes were similar for a given BNP
level (48). NP levels are also markers of the stage of
disease and may potentially guide selection of pa-
tients in the “modiﬁable” zone, which identiﬁes pa-
tients who may be neither “too well” nor “too sick” to
beneﬁt from an intervention. A post-hoc analysis of
I-PRESERVE demonstrated that patients with NT-
proBNP levels above the median of 339 pg/ml were
independently associated with the primary endpoint
of all-cause mortality and cardiovascular hospitali-
zations, whereas patients with NT-proBNP levels
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1676below the median had beneﬁcial effects from irbe-
sartan, even after adjustment for 20 covariates (49).
In the Phosphodiesterase-5 Inhibition to Improve
Clinical Status and Exercise Capacity in Heart Failure
with Preserved Ejection Fraction (RELAX) trial eval-
uating phosphodiesterase-5 inhibition in patients
with HFpEF, the median NT-proBNP levels (648 pg/
ml) were even higher than in I-PRESERVE with
similar results: no improvement in the primary end-
points of peak oxygen consumption (VO2) or 6-min
walk distance (49,50). The I-PRESERVE and the
RELAX trials suggest that there is an upper boundary
for a modiﬁable zone, above which a more advanced
disease state exists where therapies may provide lit-
tle, if any beneﬁt. In the ALDO-DHF (Aldosterone re-
ceptor blockade in Diastolic Heart Failure) trial, the
median NT-proBNP level of 148 pg/ml demonstrated
improvement of 1 coprimary endpoint, E/e0, but no
improvement in the other coprimary endpoint,
change in peak VO2, suggesting the possibility of a
lower boundary where patients are too well to beneﬁt
from therapy, in addition to an upper boundary (51).
The cutoff for NPs provides a distinct opportunity to
increase the speciﬁcity of the diagnosis of HFpEF as
well as event rates; however, choosing too high of a
level will potentially identify patients too advanced
in their disease state to beneﬁt from interventions
such as renin-angiotensin aldosterone system ther-
apy (48).
NP levels are highly affected by the confounding
comorbidities of atrial ﬁbrillation, renal insufﬁciency,
and obesity. NP levels are lower in obese patients
with HFpEF and are independently associated with a
favorable adiposity proﬁle (52). Compared with pa-
tients with normal body mass index, NP levels are
signiﬁcantly lower in obese and overweight patients
after adjustment for important clinical characteris-
tics, including atrial ﬁbrillation (median values of
608, 227, and 396 pg/ml, respectively) (53,54). For
example, the NT-proBNP level was revised in the
RELAX trial evaluating sildenaﬁl secondary to the
“falsely” low NP levels found in obese patients with
hemodynamically-validated HFpEF. NP levels are
known to be higher in patients with atrial ﬁbrilla-
tion (55); however, patients with atrial ﬁbrillation
and obesity have an inverse relationship between
body mass index and circulating levels of NT-
proBNP, suggesting that the underlying pathophysi-
ology of obesity may reduce NP levels (56). HFpEF
patients with renal impairment are known to have
elevated NP levels, with NT-proBNP rising more
than BNP; more than 79% of HFpEF patients with
BNP levels >1,000 pg/ml have chronic renal insufﬁ-
ciency (57,58).Choosing a threshold and ceiling level for trial
entry on the basis of NP level requires considering
several key factors for success: 1) the tradeoff be-
tween speciﬁcity and sensitivity for the diagnosis of
HFpEF; 2) feasibility of patient recruitment; 3) clinical
setting (acute decompensated HFpEF vs. chronic
stable HFpEF); and 4) comorbidities. More recent
clinical trials have raised the entry criteria for NP
from TOPCAT levels of 100 and 360 pg/ml for BNP
and NT-proBNP, respectively, to PARAMOUNT’s
NT-proBNP threshold of 400 pg/ml (19,20). The
PARADIGM-HF (Prospective comparison of ARNI with
ACEI to Determine Impact on Global Mortality and
morbidity in Heart Failure) trial used a cutoff of 150
and 600 pg/ml, respectively, for BNP and NT-proBNP
for patients without an HF hospitalization in the
previous 12 months and 100 and 400 pg/ml, respec-
tively, for patients with a HF hospitalization in the
previous 12 months (59). NP levels are 1 of the key
inclusion criteria that are most speciﬁc for patients
with HFpEF with resultant increases in event rates.
Careful adjustment upward or downward of NP
threshold on the basis of comorbidities will enrich the
preferred HFpEF phenotype and result in higher
event rates.
ATRIAL FIBRILLATION
Atrial ﬁbrillation is 1 of the most common comor-
bidities in patients with HFpEF and coexists in 21%
to 34% of patients in large registries and 4% to
61% of patients in HFpEF clinical trials (Table 2).
HFpEF patients with atrial ﬁbrillation are older,
have higher NP levels, larger left atrial volume in-
dexes, and are independently associated with death
after adjustment for covariates compared with
HFpEF patients in sinus rhythm (60). The PROTECT
(Placebo-Controlled Randomized Study of the
Selective Adenosine A1 Receptor Antagonist Rolo-
fylline for Patients Hospitalized for Acute Decom-
pensated Heart Failure and Volume Overload to
Assess Treatment Effect on Congestion and Renal
Function) trial is 1 of many with a high enrollment
of patients with atrial ﬁbrillation (57%), raising
the question of whether acute symptoms may be
related to exacerbated atrial ﬁbrillation rather than
to acutely decompensated HFpEF (61). Most drugs
targeting HFpEF may not improve symptoms in
patients with a primary diagnosis of atrial ﬁbrilla-
tion; thus, studying these patients may confound
results and limit our ability to detect HFpEF-speciﬁc
treatment effects. However, basing entry criteria on
NT-proBNP or left atrial size would bias toward
the selection of patients with atrial ﬁbrillation (who
FIGURE 1 Inclusion Criteria That Alter Event Rates in HFpEF Clinical Trials
Ejection Fraction
Hemodynamics Enrolled HFpEFPatient
Clinical
Diagnosis of HF
Atrial Fibrillation
& Other
Comorbidities
Natriuretic
Peptide Levels
Prior HF
Hospitalization
Representative inclusion criteria used in past, present, and future clinical trials of patients
with HFpEF. HF ¼ heart failure; HFpEF ¼ heart failure with preserved ejection fraction.
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1677have higher levels of NP and larger left atrium, in-
dependent of HF). Furthermore, some have argued
that atrial ﬁbrillation should be considered part and
parcel of the HFpEF disease syndrome because
almost two-thirds of HFpEF patients have atrial
ﬁbrillation during the course of their disease:
approximately 29% of patients with HFpEF have
atrial ﬁbrillation before diagnosis; 23% have atrial
ﬁbrillation at the time of diagnosis; and 32% go on
to develop atrial ﬁbrillation within 3 to 4 years of
follow-up (60). In PARAMOUNT, the mandate for an
NT-proBNP cutoff for entry resulted in an over-
representation of patients with atrial ﬁbrillation, in
whom higher levels of NT-proBNP are expected and
are related to atrial ﬁbrillation and the resultant
increased left atrial size and circulatory volume,
leading to increased release of NPs. If, as expected,
more patients have atrial ﬁbrillation without true
HFpEF, then there would be a signiﬁcant effect on
PARAMOUNT’s goal to detect LCZ696’s efﬁcacy in
patients with HFpEF, as LCZ696 is not known to
affect the underlying pathophysiology of atrial
ﬁbrillation. The signiﬁcant number of enrolled pa-
tients with atrial ﬁbrillation led to a cap on the
absolute percentage of patients with atrial ﬁbrilla-
tion that could be recruited.
Strategies to address this dilemma include: 1)
introduction of a cap on the proportion of patients
with atrial ﬁbrillation who can be recruited; and 2)
using different NT-proBNP cutoffs for those with and
without atrial ﬁbrillation.FIGURE 2 Strategies to Enrich Event Rates in HFpEF Clinical Trials
Deplete Event Rates 
NP Levels 
Use comorbidities without NP thresholds 
Use misguided EF threshold 
Enr
Vali
Vali
NYH
Dys
Enr
Use
N
Use
The appropriate use of speciﬁc inclusion criteria and targeted threshold
designed clinical trials of patients with HFpEF. EF ¼ ejection fraction; N
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Hemodynamics, measured invasively and non-
invasively, yield an objective assessment of pressures
in the venous circulation. Central venous pressure
increases when increased circulatory volume occurs
from tricuspid regurgitation or right ventricle failure,ich Event Rates 
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P ¼ natriuretic peptide; NYHA ¼ New York Heart Association;
CENTRAL ILLUSTRATION Methodological Recommendations to
Enhance Clinical Trial Success Through Increased Event Rates
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Kelly, J.P. et al. J Am Coll Cardiol. 2015; 65(16):1668–82.
Previous and ongoing clinical trial inclusion criteria and methodological considerations are
presented with recommendations to highlight the complexity of clinical trial design with
associated recommendations to enhance event rates and future clinical trial success.
CPET ¼ cardiopulmonary exercise testing; EF ¼ ejection fraction; HF ¼ heart failure;
HFpEF ¼ heart failure with preserved ejection fraction; NP ¼ natriuretic peptide;
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide.
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1678and can be estimated fairly accurately through echo-
cardiography. Hemodynamic measurements help
discern which patients have the diagnosis of HF when
the usual selection criteria are not conclusive. Pul-
monary hypertension, deﬁned as pulmonary artery
systolic pressure (PASP) >35 mm Hg, is frequently
caused by left-sided HF, is derived from the tricuspid
velocity, and is highly prevalent, with estimates as
high as 83% of patients with HFpEF (62), whereas
pulmonary capillary wedge pressure (PCWP) is esti-
mated from the ratio of early transmitral ﬂow velocityto early mitral annular diastolic velocity. Normal
ﬁlling pressures and other hemodynamic parameters,
such as PCWP, PASP, and left ventricular end-diastolic
pressure at rest followed by normal ﬁlling pressures
during exercise, exclude the diagnosis of HF. In
contrast, if ﬁlling pressures increase in proportion to
the increase in PCWP, then a diagnosis of HFpEF is
suggested (63–65). Other related diagnoses, such as
pulmonary arterial hypertension, can also be clearly
identiﬁed during right heart catheterization.
However, outside of small studies evaluating
hemodynamics in patients with equivocal diagnoses,
invasive hemodynamic measurements are infre-
quently used, and there is limited data from clin-
ical trials conﬁrming that these measurements
enhance event rates. The RELAX trial evaluating
phosphodiesterase-5 inhibition utilized an alternative
entry criteria for elevated left ventricular end-
diastolic pressure or PCWP if other criteria were not
met in a small number of unreported patients (50).
Cardiopulmonary exercise testing (CPET) provides
additive information to hemodynamics that may help
exclude HF with normal tests and conﬁrm or suggest
a HF diagnosis with abnormal results (66). CPET
measurements obtained during exercise, including
the gas exchange parameters, peak VO2, and the slope
of the relationship between ventilation and carbon
dioxide production, are independently associated
with mortality and are strong independent predictors
of mortality (39). A study evaluating serelaxin
demonstrated signiﬁcant reductions in peak PCWP
without changes in cardiac index, and a CPET with
echocardiography study in patients with HFpEF
treated with ivabradine, which revealed improved
metabolic equivalents, peak VO2, and reduced E/e0,
provided the impetus to pursue larger clinical trials
on these 2 promising therapies (67,68).
Guazzi et al. (69) demonstrated signiﬁcant im-
provements in mean pulmonary artery pressure,
right atrial pressure, pulmonary vascular resistance,
tricuspid annular systolic excursion, and EF using
invasive hemodynamics obtained in 44 patients
with HFpEF randomized to placebo or sildenaﬁl
with beneﬁts through 12 months of follow-up in
the patients with baseline evidence of chronically-
elevated left ventricular ﬁlling pressures. Guazzi’s
work led to further investigation of sildenaﬁl’s
phosphodiesterase-5 inhibition in the RELAX clinical
trial of 216 patients with endpoints closely related
to hemodynamics: change in peak VO2 and 6-min
walk distance (50). After 24 weeks, there were no
signiﬁcant changes in peak VO2 or 6-min walk dis-
tance; however, hemodynamic-related measure-
ments of E/e0, left atrial volume index, and PASP were
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ﬁlling pressures. Cardiovascular hemodynamics ob-
tained from noninvasive and invasive measurements
are very helpful for the conﬁrmation or exclusion of
patients who do not meet diagnostic criteria from the
usual selection criteria. However, the actual effect of
adding hemodynamic measurements to drive event
rates in clinical trials remains unknown, and future
inclusion in pilot studies and clinical trials are needed
to verify their value.
LESSONS LEARNED
HF remains a clinical diagnosis that may be enhanced
by weighing and/or limiting the patient selection
criteria discussed herein, including EF, prior HF hos-
pitalization, NP levels, comorbidities such as atrial
ﬁbrillation, clinical diagnosis of HF, and hemody-
namics (Figure 1). In addition to balancing patient se-
lection criteria, clinical trial design, implementation,
and integration of novel diagnostic techniques are
paramount to discovering future therapies for HFpEF
(Figure 2). Enrolling patients quickly prevents cross-
over to the treatment intervention, as evidenced by a
restrictive analysis of PEP-CHF that trended toward
clinical signiﬁcance (p ¼ 0.055) for the primary end-
point of all-cause mortality and unplanned HF hospi-
talization in the ﬁrst year, with the secondary endpoint
of unplanned hospitalization for HF signiﬁcant
(p ¼ 0.033) (17). Implementing important patient-
centered outcomes through the use of all hospitaliza-
tions, instead of only ﬁrst hospitalizations, can drive
important event rates (70). Factoring in the expected
differences in event rates across geographical and in-
ternational regions on the basis of past event rates
related to differences in clinical and socioeconomic
practices across the world (Table 2), as evidenced by
post-hoc analyses from the TOPCAT trial demon-
strating clinical beneﬁt in the Americas (hazard ratio:
0.82) compared with Russia/Republic of Georgia
(hazard ratio: 1.1) will allow for proper statistical power
to detect meaningful differences (19,31).
Recent studies evaluating new imaging techniques
measuring impaired systolic function in patients with
HFpEF through 3-dimensional speckle, left atrial, and
longitudinal strain analyses, which are associated
with mortality and may provide opportunities to
enhance patient selection and event rates (71–76).
Emerging and novel biomarkers, such as cystatin C,
galectin-3, and growth differentiation factor-15,
may help phenotype, risk-stratify, and identify pa-
tients with or at risk for HFpEF (77–79). Evidence
continues to mount from studies that evaluated iso-
lated comorbidities, such as coronary disease (80)and diabetes mellitus (81), in patients with HFpEF,
demonstrating worse mortality, although splitting
the heterogeneous HFpEF population into targeted
groups with distinct phenotypes may lead to thera-
peutic advances (82,83). Shah et al. (84) recently used
statistical learning algorithms in 400 patients with
HFpEF to perform an unbiased clustering analysis
of dense phenotypic data to “phenomap” patients
with HFpEF into more homogeneous subclasses.
Combinations of “omics,” cluster analyses, and phe-
nomapping result in novel classiﬁcations of HFpEF
that may simplify this heterogeneous population into
discernable classiﬁcations that ultimately allow for
targeted pharmaceutical therapies (85,86). Integra-
tion of lessons learned from previous HFpEF clinical
trials with current patient selection criteria and
emerging and novel imaging, biomarker, and pheno-
type classiﬁcation schema provide a unique scaffold
to advance HFpEF clinical trial success.
CONCLUSIONS
Promising new therapeutic options on the basis of
sound scientiﬁc rationale and observational data,
such as the recently-published study on angiotensin-
neprilysin inhibitors (59), may prove to beneﬁt pa-
tients with HFpEF. However, clinical trials in HFpEF
using standard, mortality-reducing therapies known
in HFrEF have thus far been neutral. To optimize
clinical trial effectiveness, trials in patients with
HFpEF should consider inclusion of patients with the
common comorbidities that drive HFpEF’s underlying
pathophysiology through the balanced use of the
following key inclusion and exclusion criteria: uni-
versal EF cutpoint; appropriate NP-level thresholds;
limited number of patients with atrial ﬁbrillation (with
a higher NP cut-point); and use of a clearly-deﬁned
history of HF and diagnosis of previous HF (Central
Illustration). Attaining hemodynamic measurements
related to HFpEF through the use of echocardiogra-
phy, cardiopulmonary exercise testing, and invasive
hemodynamics may complement or validate chal-
lenging patients. Thoughtful clinical trial design that
incorporates the lessons learned from previous and
ongoing clinical trials in patients with HFpEF will
provide the trial landscape necessary to determine if
future therapies actually improve the outcomes and/
or quality of life in patients with HFpEF.
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